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INTRODUCTION
A concept in traditional medicine called ‘natural 
is safe’ has been developing and led the massive use 
of herbal products for health benefits. This concept 
in some cases is not only far from the truth, but can 
also be dangerous. Some of the most toxic substances 
to human body come from nature. When a synthetic 
drug that contains a single active chemical substance 
can be toxic, more potential toxic effects are likely 
expected from a natural herb which may contain 
hundreds of chemical compounds.1 Many cases of 
serious adverse reactions from the consumption of 
herbal medicine have been reported across the globe.2–4 
In addition, the adverse reactions of herbal medicine 
are also experienced by patients treated in hospital 
settings who receive conventional medications.5
Undesired effects of traditional medicine may include 
allergic reactions, toxic reactions and interactions. 
These effects can be due to several factors, such as inap-
propriate doses and length of use, bacterial or other 
chemical contaminations and mistaken plant identities. 
The safe use of traditional medicines has been a major 
concern since they have led to several adverse reactions 
that can be life-threatening.6–8 Therefore, it is necessary 
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ABSTRACT
Objective: To study the liver toxicity of Cassytha filiformis L. extract and its reversibility in 
mice. Methods: A total of 108 male mice were used to investigate the hepatotoxicity of 
Cassytha filiformis extract (CFE) and the reversibility of its toxicity to the liver. Seventy-two 
mice were treated with CFE orally for 7 consecutive days. A half of these animals were used 
to study the sleep time on propofol-induced sleep that comprised the sleep onset time (SOT) 
and duration of sleep (DOS), while another half was used for the quantitation of serum alanine 
transaminase (ALT) activity. To investigate the reversibility of the liver toxicity, thirty-six mice 
were treated with daily CFE for 7 days. Activities of ALT and alkaline phosphatase (ALP) were 
determined and the liver weight ratio was measured on day 0, 1, 3 and 7 after the termination 
of the CFE treatment. Data of liver toxicity determination were analyzed by two-way ANOVA 
followed by Duncan’s multiple range test, while data of the reversibility was analyzed by Pear-
son’s correlation. The significance level was taken at 95% of confidence interval. Results: 
CFE shortened the SOT and prolonged the DOS significantly compared with control (p<0.05). 
The activity of ALT was increased due to the toxicity of CFE. However, the ALT/ALP activities 
decreased and liver weight ratio increased gradually after the extract treatment was discon-
tinued. The trend of these data was correlated significantly (p<0.05). Conclusion: Cassytha 
filiformis L. extract is toxic to the liver but the toxicity is reversible depending on doses.
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to conduct toxicological studies to better provide 
their feasibility and utilization. WHO has encour-
aged countries to promote the safe use of herbal 
products by stimulating strategic research on the 
safety of traditional medicine intended for health 
benefits.9
Following several reports on the traditional use of 
Cassytha filiformis as herbal medicine, the potential 
pharmacological activities of this plant have been 
extensively reported within the last decade. The 
plant effect comprises several activities in a wide 
range of physiological systems, mainly cardiovascular 
function. Many studies have proven that this her-
baceous plant exhibits antiplatelet and vasorelax-
ing effect,10 antihypertensive,11-12 diuretic effect13 
and blood glucose lowering effect.14 Other studies 
have also confirmed different effects of the plant, 
including uterotonic,15 anticancer,16-17 immunosup-
pressive18 and anti-infectious.17,19-20 These properties 
make this plant a very promising herbal medicine 
for the development of pharmaceuticals. However, 
toxicological studies on this potential medicinal 
plant are still limited.
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The toxicity studies on various extracts and fractions of C. filiformis have 
shown varying results in experimental animals. Most of them suggest 
that the plant is generally non-toxic for most organ systems, such as 
for the haematologic functions, plasma biochemical parameters,21 and 
kidney functions.22 Our previous study has also highlighted that the 
acute administration of ethanolic extract of this plant does not affect the 
organ weight ratio of some major organs, but may cause delayed toxicity, 
including to the liver.23
Liver cells are well known to have a remarkable ability to regenerate 
compared to other organs.24 The damaged cells due to several stimuli 
such as infections and chemicals can be replaced by the new liver tissue 
in just a few days.25 The present study is intended to investigate the toxicity 
of C. filiformis extract to the liver function, including in the metabolism 
as the main role of this organ. In addition, the reversibility of this toxic 
effect is also studied through the determination of liver enzymes activity.
MATERIALS AND METHODS
Drugs and chemicals
Ethanol and n-hexane were purchased from Bratachem (Brataco PT, 
Indonesia). Propofol (Fresofol®) was the product of Fresenius Kabi 
(Indonesia). The assay kit of alanine transaminase (ALT) and alkaline 
phosphatase (ALP) was purchased from DiaSys Diagnostic Systems 
GmbH (Germany). All materials were used as received. 
Cassytha filiformis extract preparation 
The extract was produced from the whole part of Cassytha filiformis 
plant (family Lauraceae) collected from Padang City, West Sumatra, 
Indonesia. The exact species of the plant was confirmed in Herbarium 
of Andalas University (ANDA). The entire extraction process was con-
ducted according to our previous work.12
Determination of hepatotoxicity of Cassytha filiformis 
extract 
A number of 72 male mice weighing 25-30 g and aged 2-3 months old 
were acclimatized to normal laboratory condition for one week before 
any experimental procedure. The mice were provided drinking water 
and standard chow ad libitum. A half of the animals were used for the 
determination of sleep time, while another half were used to evaluate 
serum alanine transaminase (ALT) activity. The animals received daily 
oral administration of C. filiformis extract (CFE) at the doses of 2.5; 5; 
and 10 mg/kg with a control group receiving distilled water. All formulas 
were added with surfactant to produce a homogenous suspension. The 
animals were also grouped based on the duration of administration: 1, 
3 and 7 days. 
The evaluation of sleeping time behavior consisted of sleep onset time 
(SOT) and duration of sleep (DOS). Propofol 140 mg/kg was adminis-
tered through intraperitoneal injection 2 h after the last administration 
of the extract to induce sleep. The SOT and DOS were recorded by using 
the loss and recovery of righting reflex.26 Meanwhile, ALT activity was 
determined using UV-Visible spectrophotometry (Shimadzu-1700®, 
Japan).
Evaluation of reversibility of liver toxicity 
Another 36 male mice were divided into 3 groups and treated with CFE 
at the doses of 5, 10 and 20 mg/kg orally. The extract was discontinued 
after 7 days administration. The activities of alanine transferase (ALT) 
and alanine phosphatase (ALP) were determined on day 0, 1, 3 and 7 
after the discontinuation of CFE administration. The liver weight ratio 
was also measured. All protocols for the animals have been approved by 
the Ethics Committee of Faculty of Medicine, Andalas University No. 
083/KEP/FK/2016.
Statistical analysis
The data were presented as mean ± SEM. A two-way analysis of variance 
(ANOVA) was used for multiple comparisons of toxicity parameters. 
Any significant variation within groups was further analyzed by Duncan’s 
multiple range test. The reversibility of parameters after discontinuation 
of extract administration was analyzed with Pearson’s correlation. P values 
of <0.05 were considered to be statistically significant for all analyses.
RESULTS 
Effect of Cassytha filiformis extract to sleep onset time 
(SOT)
Both doses and duration of C. filiformis extract (CFE) administration 
influenced the sleep onset time (SOT) significantly (p< 0.05). All doses 
of the extract caused a significant delay in the SOT as compared with 
control. However, there was no significant variation of SOT among the 
extract doses. In contrast, the duration of treatment caused a significant 
variation in the SOT, in which the longer the duration of treatment, 
the shorter the SOT. The shortest onset was demonstrated by the highest 
dose of extract (10 mg/kg) and the longest duration of treatment (7 days). 
This indicates a strong effect of the extract treatment to the function of 
the liver in the metabolism of propofol. The SOT of the mice after the 
administration of the extract is presented in Table 1. 
Effect of Cassytha filiformis extract to the duration of 
sleep (DOS)
The doses and duration of C. filiformis extract (CFE) treatment also 
influenced the duration of sleep (DOS) significantly (p< 0.05). Extract 
in the doses of 5 and 10 mg/kg caused a significant increase in the DOS 
as compared with control. Higher doses were likely to prolong the DOS. 
Meanwhile, the duration of treatment caused a significant variation in 
the DOS. Seven days of treatment caused the longest DOS and was 
significantly different as compared with 1 and 3 days of treatment. The 
longest DOS was demonstrated by the highest dose of extract, 10 mg/kg. 
The DOS of the mice after the administration of the extract is presented 
in Table 2. The effect of CFE to the sleep time (both SOT and DOS) is 
shown in Figure 5. 
Effect of Cassytha filiformis extract to the activity of 
alanine transferase (ALT)
The administration of extract caused a significant difference to the activity 
of ALT (p<0.05). Higher doses increased the average activity of ALT, 
indicating that the extract induced a liver injury. Meanwhile, the 
duration of treatment did not cause a significant variation to the average 
Table 1: The influence of Cassytha filiformis extract to sleep onset time. 
Doses  
(mg/kg)
Sleep onset time (second)
Average1 day 3 days 7 days
Control 279 ± 35.01 260 ± 9.07 255 ± 33.93 264.8 ± 14.77a
Extract 2.5 376 ± 39.75 325 ± 11.83 278 ± 17.70 326.8 ± 19.19b
Extract 5 387 ± 42.21 367 ± 20.95 193 ± 24.47 316.8 ± 34.38b
Extract 10 424 ± 33.22 303 ± 7.57 216 ± 22.21 314.7 ± 32.32b 
Average 366.8 ± 30.92p 314.0 ± 22.49q 236.1 ± 19.00r
Data are expressed as mean ± SEM. Average data with different superscript are 
significantly different (P<0.05).
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Table 2: The influence of Cassytha filiformis extract to the duration of 
sleep. 
Doses  
(mg/kg)
Duration of sleep (second)
Average1 day 3 days 7 days
Control 1877 ± 218.41 1738 ± 134.87 1933 ± 295.32 1849 ± 116.62a
Extract 2.5 1879 ± 232.89 2409 ± 338.00 1619 ± 142.18 1969 ± 170.97a
Extract 5 1584 ± 188.48 2443 ± 144.36 4804 ± 363.78 2944 ± 497.44b
Extract 10 1737 ± 82.56 3198 ± 66.06 4084 ± 144.46 3006 ± 345.97b
Average 1769 ± 180.59p 2447 ± 170.83q 3110 ± 236.44r
Data are expressed as mean ± SEM. Average data with different superscript are 
significantly different (P<0.05).
Table 3: The influence of Cassytha filiformis extract to ALT activities. 
Doses  
(mg/kg)
ALT Activity (IU/L)
Average1 day 3 days 7 days
Control 53.92 ± 7.606 51.06 ± 8.672 48.23 ± 2.344 51.06 ± 3.496a
Extract 2.5 60.14 ± 9.269 57.35 ± 7.982 53.73 ± 5.502 57.07 ± 3.982a
Extract 5 51.61 ± 7.996 62.39 ± 3.626 64.26 ± 4.160 59.42 ± 3.428ab
Extract 10 54.99 ± 3.485 70.29 ± 10.644 84.20 ± 5.461 69.83 ± 5.543b
Average 55.17 ± 1.801p 60.27 ± 4.062p 62.60 ± 7.933p
Data are expressed as mean ± SEM. Average data with different superscript are 
significantly different (P<0.05).
Table 4: Reversibility of liver function after the termination of Cassytha 
filiformis extract treatment.
Correlation score
Liver weight 
ratio ALT activity ALP activity 
Day after extract 
discontinued
r 0.518** -0.530** -0.333*
p 0.001 0.001 0.047
n 36 36 36
Analyzed with Pearson Product-Moment Correlation (r = Pearson correlation 
coefficient; p = significance level; n = number of data). ** Correlation is significant 
at the 0.01 level, *correlation is significant at the 0.05 level.
Figure 1: Liver weight ratio after the termination of Cassytha filiformis extract 
treatment.
Figure 2: Activity of alanine transferase (ALT) after the termination of 
Cassytha filiformis extract treatment.
Figure 3: Activity of alkaline phosphatase (ALP) after the termination of 
Cassytha filiformis extract treatment.
ALT (p> 0.05), but the extract caused an increase for a longer duration 
treatment, especially in the doses of 5 and 10 mg/kg. The ALT activity of 
the mice after the administration of CFE is shown in Table 3. 
Liver weight ratio after the termination of Cassytha 
filiformis extract administration
The liver weight ratio of the mice was significantly correlated with the 
day after discontinuation of extract administration (P< 0.05) and signi-
ficantly affected by the dose of the extract. The liver weight ratio of the 
mice increased with time according to dose (Figure 1). The correlation 
coefficient of liver weight ratio with time is 0.518 and the scatter plot of 
the correlation is shown in Figure 5A.
Activities of alanine transferase (ALT) and alkaline 
phosphatase (ALP) after the termination of Cassytha 
filiformis extract administration 
The ALT activity was significantly correlated with time after discontinu-
ation of extract (p<0.05). The animal ALT levels decreased over time and 
proportional to the dose. The ALT of the animals treated with lower dose 
decreased faster compared to those treated with higher dose. Similarly, 
the animal ALP activity after discontinuation of CFE administration was 
significantly affected by dose and time (p<0.05). The ALP activity also 
decreased after administration of the extract was discontinued and was 
accordingly to the dose. The decrease of ALT and ALP activities after 
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discontinuation of the extract are demonstrated in Figure 2 and 3. The 
correlation coefficient of ALT and ALP with time are -0.530 and -0.333, 
respectively (Table 4). The scatter plots of the correlation is shown in 
Figure 5B and 5C. 
DISCUSSION
The new concept in herbal medicine suggests that natural products may 
come as a good solution along with current best medical practices. One 
very important aspect to take into account is to promote high-quality 
studies to pursue “evidence-based herbal medicine”, including the evalu-
ation of its safety.1 Consequently, the very potential of Cassytha fili-
formis should be explored for its safety data, mainly for major organs. 
The possible toxicity of this plant to the liver, one of the most common 
organs that may be damaged from the use of herbal remedies, needs to 
be examined. In addition, the reversibility of its toxic effect is also an 
important attribute since the liver is a metabolizing organ with an amazing 
regenerative capacity.24 This information will guide those interested in 
preparing a product using this plant, especially for dose arrangement in 
order to guarantee its safe use.
In this study, we investigated the toxic effect of seven days use of 
C. filiformis extract to the liver function of mice using enzyme activity 
and sleep time in propofol-induced sedation as indicators. The reversibility 
of the toxic effect was furtherly studied through the trend of liver weight 
ratio and enzymes activity changes in seven days after the extract treatment 
was terminated. We found that the extract exhibited hepatotoxicity indi-
cated by a significant decrease in liver function. However, this toxic effect 
was reversible, in which the indicators of liver function were approaching 
the normal rate after the discontinuation of extract treatment. 
Propofol is a popular sedative agent well known for its rapid onset of 
action, short half-life and favorable recovery profile for anesthesia. 
The metabolism of propofol is mainly in the liver, bio transformed via 
a cytochrome P-450 dependent pathway or undergoes quick direct 
glucuronidation.27 The damaged liver may cause a disturbance in the 
metabolism of propofol, resulting in the altered pharmacokinetic profile 
of the drug, predominantly the onset time and the duration of action. 
Therefore, the sleep onset time (SOT) and duration of sleep (DOS) due 
to the administration of propofol are valuable parameters to assess the 
function of the liver. In addition, the sleeping behavior is closely related 
to the function of the liver. Some human studies have confirmed that 
liver injury, such as cirrhosis, can cause major changes in sleep pattern. 
The degree and quality of sleep are also reported to correlate to the liver 
function.28-29
The hepatotoxicity of C. filiformis extract in the present study was 
confirmed by a significant delay in the onset of action of propofol, 
indicated by earlier sleep of the mice (Table 1). Altered liver function 
due to the extract is also indicated by the prolongation of propofol effect. 
The data demonstrate a significant increase of sleep time in mice treated 
with higher dose or longer duration of extract administration (Table 2). 
Propofol is basically a short-acting anesthesia. The short duration of 
effect of propofol is reported due to its rapid clearance combined with 
its slow diffusion to central compartment. This drug is metabolized in 
the liver to less active metabolites that can be eliminated through renal 
excretion.30-31 In the present study, the extract is likely to cause a decrease 
on the biotransformation of propofol to its less active metabolites, resulting 
in prolonged duration of sedation effect. Figure 4 demonstrates the sleep 
and wake time of the mice treated with multiple doses and different 
duration of extract treatment.
Liver cell damage begins with an exposure of liver cell membranes to 
toxic substances resulting in an increase in cell membrane permeability. 
This condition will lead to a decrease in its ability to prevent passive 
diffusion of ions from entering the cell. The extracellular calcium ion 
enters the cell and accumulates in the mitochondria causing swelling 
that triggers mitochondrial damage. The accumulation of calcium ions 
in the mitochondria disrupts the metabolism of oxidative phosphorylation, 
decreases oxidative phosphorylation and ATP, as well as disturbs the 
ionic balance. These will result in a decrease of cell pH that will affect 
and damage the lysosome membrane, resulting in the breakdown of 
lysosomes and the release of enzymes into the cytoplasm.32
On the other hand, a decrease in ATP production will also decrease 
Na+K+ATPase function. This situation will lead to an accumulation of 
intracellular Na+ and increases the cellular osmotic pressure. The water 
directly passes passively from outside of the cell into the cell following 
the concentration gradient and causes continuous cell swelling resulting 
in cell lysis. As the result, cell wall will rupture and intracellular enzymes 
will be released into the bloodstream. An increase of these enzymes, e.g. 
alanine transferase (ALT), is a good marker of liver cells damage.33 
In this study, the activity of ALT and ALP enzymes increased after the 
administration of C. filiformis extract, despite their levels were ranged 
within normal values. This indicates that the extract is slightly toxic to 
the liver. Toxic effect of this extract is also reported by Quetin et al. who 
describes that the alkaloid contents of this plant exhibit cytotoxic activity 
with a non-specific topoisomerase I and II inhibition mechanism.16-17 
This non-selective inhibition may also affect the normal liver cells and 
cause cell damage.34
Fortunately, the toxic effect on the liver function is reversible, indicated 
by the decrease of mice ALT and ALP on day 3 to 7 after the extract 
was discontinued, depending on dose. The lower the dose, the faster the 
recovery. The liver weight ratio also indicates the recovery of the organ 
significantly, along with the decrease of enzyme activity (Table 4). The 
correlation of the dose and the recovery of the organ is shown in Figure 5.
Figure 4: Effect of Cassytha filiformis extract on propofol-induced sleep time 
in mice.
Figure 5: Scatter plots showing the reversibility of liver function after the 
termination of Cassytha filiformis extract treatment: A) liver weight ratio, R2 = 
0.269; B) alanine transferase (ALT) activity, R2 = 0.281; and C) alkaline phospha-
tase (ALP) activity R2 = 0.111.
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The process of cell regeneration takes different time in different organisms. 
This cell regeneration depends on the cell proliferation process. For 
mice, the peak proliferation of its cells takes about 24 h, with the peak of 
36-42 h.35 Liver cell injury found in this study is indicated by a decrease 
in the liver weight ratio especially in mice treated with high dose but 
then increased by time. Weight loss of the liver may result from the lysis 
of hepatocytes. Thus, the toxic effect of the extract on the liver decreases 
its size but then returns to normal due to the liver cell regeneration.
CONCLUSION
In conclusion, these results suggest that the defatted extract of Cassytha 
filiformis is toxic to the liver, but the toxicity is reversible depending on 
the dose. More toxicity studies of this plant to other organ systems are 
required to support its safe use beyond its potential efficacy.
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GRAPHICAL ABSTRACT SUMMARY
• Cassytha filiformis was extracted by using ethanol and then further defatted 
with n-hexane. The extract was administered orally to the mice to investigate 
the hepatotoxicity of the extract and its reversibility.
• The extract caused hepatotoxicity, indicated by increased activity of alanine 
transferase (ALT) and alteration on the metabolism of propofol that was in-
duced to the mice.
• Altered metabolism of propofol was marked by the delay on the sleep onset 
time (SOT) and prolongation on the duration of sleep (DOS) in propofol-induced 
sleep in mice.
• The hepatotoxicity of the extract was reversible, indicated by improved liver 
weight ratio and decreased activity of alanine transferase (ALT) and alkaline 
phosphatase (ALP) after the termination of the extract.
• The reversibility of hepatotoxicity of Cassytha filiformis was depending on the 
dose, in which the lower dose and shorter duration of administration showed 
better recovery for the liver.
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